Symbols / KYMR $88.77 +0.79% Kymera Therapeutics, Inc.
KYMR Chart
About
Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing KT-621, an oral STAT6 degrader in Phase 2b clinical trials for moderate to severe atopic dermatitis, asthma, COPD, EoE, CRSwNP, CSU, PN, BP, and others; KT-579, an oral IRF5 degrader in Phase 1 trials for autoimmune diseases such as systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, SSc, DM, and others; KT-485/SAR447971, IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa and atopic dermatitis; and cyclin-dependent kinase 2 (CDK2) with broad oncology treatment potential, including in breast cancer and other solid tumors. The company has a strategic alliance with Sanofi S.A. for the development of drug candidates targeting IRAK4 outside the oncology and immuno-oncology fields. Kymera Therapeutics, Inc. was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
Fundamentals
Scroll to Statements| Market Cap | 7.25B | Enterprise Value | 6.48B | Income | -311.35M | Sales | 39.21M | Book/sh | 19.42 | Cash/sh | 10.39 |
| Dividend Yield | — | Payout | 0.00% | Employees | 238 | IPO | — | P/E | — | Forward P/E | -22.15 |
| PEG | — | P/S | 184.83 | P/B | 4.57 | P/C | — | EV/EBITDA | -19.13 | EV/Sales | 165.29 |
| Quick Ratio | 10.19 | Current Ratio | 10.47 | Debt/Eq | 5.21 | LT Debt/Eq | — | EPS (ttm) | -3.69 | EPS next Y | -4.01 |
| EPS Growth | — | Revenue Growth | -61.20% | Earnings | 2026-05-08 | ROA | -15.88% | ROE | -25.78% | ROIC | — |
| Gross Margin | 0.00% | Oper. Margin | -34.11% | Profit Margin | 0.00% | Shs Outstand | 81.64M | Shs Float | 54.43M | Short Float | 15.28% |
| Short Ratio | 14.46 | Short Interest | — | 52W High | 103.00 | 52W Low | 28.06 | Beta | 2.29 | Avg Volume | 714.99K |
| Volume | 401.62K | Target Price | $119.14 | Recom | Strong_buy | Prev Close | $88.07 | Price | $88.77 | Change | 0.79% |
Valuation Models
Price estimates from analyst targets and simple models.
Ratings
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-03-03 | main | UBS | Buy → Buy | $128 |
| 2026-03-02 | main | Citigroup | Buy → Buy | $120 |
| 2026-03-02 | main | Stephens & Co. | Overweight → Overweight | $100 |
| 2026-02-26 | main | BTIG | Buy → Buy | $134 |
| 2026-02-26 | main | Piper Sandler | Overweight → Overweight | $140 |
| 2026-02-03 | reit | BTIG | Buy → Buy | $138 |
| 2026-01-28 | main | Barclays | Overweight → Overweight | $133 |
| 2026-01-15 | reit | BTIG | Buy → Buy | $138 |
| 2026-01-06 | down | Wolfe Research | Outperform → Peer Perform | — |
| 2025-12-22 | main | B. Riley Securities | Buy → Buy | $117 |
| 2025-12-16 | main | RBC Capital | Outperform → Outperform | $103 |
| 2025-12-11 | main | Stephens & Co. | Overweight → Overweight | $110 |
| 2025-12-11 | main | Mizuho | Outperform → Outperform | $120 |
| 2025-12-10 | main | JP Morgan | Overweight → Overweight | $125 |
| 2025-12-09 | main | Jefferies | Buy → Buy | $122 |
| 2025-12-09 | main | Citigroup | Buy → Buy | $110 |
| 2025-12-09 | main | Wells Fargo | Overweight → Overweight | $116 |
| 2025-12-09 | main | Truist Securities | Buy → Buy | $116 |
| 2025-12-09 | main | Oppenheimer | Outperform → Outperform | $120 |
| 2025-12-09 | main | Morgan Stanley | Overweight → Overweight | $127 |
- KYMR (NASDAQ: KYMR) insiders file Form 144 to sell shares - Stock Titan Wed, 22 Apr 2026 20
- KYMR Kymera Therapeutics posts wider than expected Q4 2025 loss even as shares edge slightly higher. - Special Dividend - Xã Thanh Hà hu, 23 Apr 2026 07
- Avoiding Lag: Real-Time Signals in (KYMR) Movement - Stock Traders Daily Wed, 22 Apr 2026 05
- Kymera Therapeutics COO sells $589,598 in KYMR stock - Investing.com hu, 16 Apr 2026 23
- Cash per share of Kymera Therapeutics, Inc. – NASDAQ:KYMR - TradingView ue, 21 Apr 2026 09
- KYMR Stock Up as FDA Grants Fast Track Designation to Asthma Drug - Yahoo Finance ue, 14 Apr 2026 07
- Affiliate sales and option exercise at KYMR (NASDAQ: KYMR) — multiple 10b5-1 trades - Stock Titan Wed, 22 Apr 2026 20
- Will FDA Fast Track for KT-621 and Gilead’s KT-200 Deal Change Kymera Therapeutics' (KYMR) Narrative - simplywall.st Sun, 19 Apr 2026 23
- Kymera Therapeutics, Inc. (NASDAQ:KYMR) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat Sat, 18 Apr 2026 06
- Kymera Therapeutics (KYMR) to present Phase 1b BroADen trial data for KT-621 at AAD 2026 - MSN Sun, 19 Apr 2026 15
- Kymera Therapeutics, Inc. Common Stock KYMR ) Stock Price Today & Analysis - Gotrade ue, 13 Jan 2026 02
- KYMR Kymera Therapeutics posts wider than expected Q4 2025 loss even as shares edge slightly higher. - ROA - Xã Châu Thành Wed, 22 Apr 2026 15
- KYMR (KYMR) Form 144 shows Atlas Venture and Bruce Booth proposed sales - Stock Titan Wed, 22 Apr 2026 20
- Jeremy Chadwick Sells 7,600 Shares of Kymera Therapeutics (NASDAQ:KYMR) Stock - MarketBeat hu, 02 Apr 2026 07
- Insider Selling: Kymera Therapeutics (NASDAQ:KYMR) COO Sells 5,251 Shares of Stock - MarketBeat hu, 16 Apr 2026 23
Insider Transactions
Financials
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
39.21
-16.70%
|
47.07
-40.11%
|
78.59
+67.84%
|
46.83
|
| Operating Revenue |
|
39.21
-16.70%
|
47.07
-40.11%
|
78.59
+67.84%
|
46.83
|
| Operating Expense |
|
384.75
+26.65%
|
303.78
+24.44%
|
244.12
+17.32%
|
208.08
|
| Research And Development |
|
316.57
+31.77%
|
240.25
+27.06%
|
189.08
+15.12%
|
164.25
|
| Selling General And Administration |
|
68.19
+7.32%
|
63.53
+15.43%
|
55.04
+25.57%
|
43.83
|
| General And Administrative Expense |
|
68.19
+7.32%
|
63.53
+15.43%
|
55.04
+25.57%
|
43.83
|
| Other Gand A |
|
68.19
+7.32%
|
63.53
+15.43%
|
55.04
+25.57%
|
43.83
|
| Total Expenses |
|
384.75
+26.65%
|
303.78
+24.44%
|
244.12
+17.32%
|
208.08
|
| Operating Income |
|
-345.54
-34.60%
|
-256.71
-55.08%
|
-165.53
-2.65%
|
-161.26
|
| Total Operating Income As Reported |
|
-349.40
-33.54%
|
-261.63
-58.06%
|
-165.53
-2.65%
|
-161.26
|
| EBITDA |
|
-302.67
-39.97%
|
-216.24
-51.00%
|
-143.20
+5.57%
|
-151.66
|
| Normalized EBITDA |
|
-298.81
-41.41%
|
-211.31
-47.56%
|
-143.20
+5.57%
|
-151.66
|
| Reconciled Depreciation |
|
8.31
+12.75%
|
7.37
+106.82%
|
3.56
+19.75%
|
2.98
|
| EBIT |
|
-310.98
-39.07%
|
-223.61
-52.36%
|
-146.77
+5.09%
|
-154.63
|
| Total Unusual Items |
|
-3.85
+21.73%
|
-4.92
|
0.00
|
0.00
|
| Total Unusual Items Excluding Goodwill |
|
-3.85
+21.73%
|
-4.92
|
0.00
|
0.00
|
| Special Income Charges |
|
-3.85
+21.73%
|
-4.92
|
0.00
|
0.00
|
| Impairment Of Capital Assets |
|
3.85
-21.73%
|
4.92
|
0.00
|
0.00
|
| Net Income |
|
-311.35
-39.08%
|
-223.86
-52.32%
|
-146.96
+5.07%
|
-154.81
|
| Pretax Income |
|
-311.35
-39.08%
|
-223.86
-52.32%
|
-146.96
+5.07%
|
-154.81
|
| Net Non Operating Interest Income Expense |
|
38.05
+0.72%
|
37.78
+103.45%
|
18.57
+187.97%
|
6.45
|
| Interest Expense Non Operating |
|
0.37
+48.59%
|
0.25
+27.04%
|
0.20
+11.36%
|
0.18
|
| Net Interest Income |
|
38.05
+0.72%
|
37.78
+103.45%
|
18.57
+187.97%
|
6.45
|
| Interest Expense |
|
0.37
+48.59%
|
0.25
+27.04%
|
0.20
+11.36%
|
0.18
|
| Interest Income Non Operating |
|
38.42
+1.03%
|
38.03
+102.65%
|
18.76
+183.27%
|
6.62
|
| Interest Income |
|
38.42
+1.03%
|
38.03
+102.65%
|
18.76
+183.27%
|
6.62
|
| Other Income Expense |
|
-3.85
+21.73%
|
-4.92
|
—
|
—
|
| Tax Rate For Calcs |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Tax Effect Of Unusual Items |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Net Income Including Noncontrolling Interests |
|
-311.35
-39.08%
|
-223.86
-52.32%
|
-146.96
+5.07%
|
-154.81
|
| Net Income From Continuing Operation Net Minority Interest |
|
-311.35
-39.08%
|
-223.86
-52.32%
|
-146.96
+5.07%
|
-154.81
|
| Net Income From Continuing And Discontinued Operation |
|
-311.35
-39.08%
|
-223.86
-52.32%
|
-146.96
+5.07%
|
-154.81
|
| Net Income Continuous Operations |
|
-311.35
-39.08%
|
-223.86
-52.32%
|
-146.96
+5.07%
|
-154.81
|
| Normalized Income |
|
-307.50
-40.45%
|
-218.93
-48.97%
|
-146.96
+5.07%
|
-154.81
|
| Net Income Common Stockholders |
|
-311.35
-39.08%
|
-223.86
-52.32%
|
-146.96
+5.07%
|
-154.81
|
| Diluted EPS |
|
—
|
-2.98
-18.25%
|
-2.52
+12.20%
|
-2.87
|
| Basic EPS |
|
—
|
-2.98
-18.25%
|
-2.52
+12.20%
|
-2.87
|
| Basic Average Shares |
|
—
|
75.04
+28.58%
|
58.37
+8.22%
|
53.93
|
| Diluted Average Shares |
|
—
|
75.04
+28.58%
|
58.37
+8.22%
|
53.93
|
| Diluted NI Availto Com Stockholders |
|
-311.35
-39.08%
|
-223.86
-52.32%
|
-146.96
+5.07%
|
-154.81
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Assets |
|
1,742.81
+78.20%
|
978.03
+69.87%
|
575.76
-4.54%
|
603.13
|
| Current Assets |
|
871.21
+70.74%
|
510.27
+25.89%
|
405.32
-3.36%
|
419.42
|
| Cash Cash Equivalents And Short Term Investments |
|
848.28
+73.56%
|
488.74
+30.37%
|
374.88
-7.93%
|
407.17
|
| Cash And Cash Equivalents |
|
357.01
+196.88%
|
120.26
+9.36%
|
109.97
+60.78%
|
68.39
|
| Other Short Term Investments |
|
491.26
+33.32%
|
368.49
+39.10%
|
264.92
-21.80%
|
338.77
|
| Receivables |
|
—
|
0.95
-94.95%
|
18.76
+639.53%
|
2.54
|
| Accounts Receivable |
|
—
|
0.00
-100.00%
|
15.00
|
0.00
|
| Other Receivables |
|
—
|
0.95
-74.83%
|
3.76
+48.29%
|
2.54
|
| Prepaid Assets |
|
—
|
—
|
—
|
—
|
| Other Current Assets |
|
22.94
+6.57%
|
21.52
+84.38%
|
11.67
+20.19%
|
9.71
|
| Total Non Current Assets |
|
871.60
+86.33%
|
467.77
+174.44%
|
170.44
-7.23%
|
183.72
|
| Net PPE |
|
85.53
-12.61%
|
97.86
-3.18%
|
101.08
+354.43%
|
22.24
|
| Gross PPE |
|
107.65
-5.52%
|
113.94
+2.17%
|
111.52
+282.75%
|
29.14
|
| Accumulated Depreciation |
|
-22.13
-37.67%
|
-16.07
-53.96%
|
-10.44
-51.46%
|
-6.89
|
| Properties |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Buildings And Improvements |
|
—
|
47.41
-10.46%
|
52.95
+494.29%
|
8.91
|
| Machinery Furniture Equipment |
|
10.92
-8.93%
|
11.99
+43.28%
|
8.37
+21.39%
|
6.90
|
| Construction In Progress |
|
—
|
—
|
—
|
1.15
|
| Other Properties |
|
53.74
-7.24%
|
57.93
+36.63%
|
42.40
+666.88%
|
5.53
|
| Leases |
|
42.99
-2.32%
|
44.01
+464.09%
|
7.80
+0.00%
|
7.80
|
| Investments And Advances |
|
771.16
+112.93%
|
362.16
+489.51%
|
61.43
-59.67%
|
152.33
|
| Other Non Current Assets |
|
14.91
+92.59%
|
7.74
-2.33%
|
7.93
-13.32%
|
9.15
|
| Total Liabilities Net Minority Interest |
|
163.15
+14.56%
|
142.42
-21.22%
|
180.79
+60.01%
|
112.98
|
| Current Liabilities |
|
83.21
+22.79%
|
67.77
-20.92%
|
85.69
+20.11%
|
71.34
|
| Payables And Accrued Expenses |
|
46.29
+13.30%
|
40.86
-0.20%
|
40.94
+28.59%
|
31.84
|
| Payables |
|
4.01
-32.96%
|
5.99
-15.35%
|
7.08
+63.21%
|
4.33
|
| Accounts Payable |
|
4.01
-32.96%
|
5.99
-15.35%
|
7.08
+63.21%
|
4.33
|
| Current Accrued Expenses |
|
42.27
+21.24%
|
34.87
+2.96%
|
33.86
+23.13%
|
27.50
|
| Current Debt And Capital Lease Obligation |
|
13.76
+4.91%
|
13.11
+106.65%
|
6.34
+60.92%
|
3.94
|
| Current Capital Lease Obligation |
|
13.76
+4.91%
|
13.11
+106.65%
|
6.34
+60.92%
|
3.94
|
| Current Deferred Liabilities |
|
22.93
+68.86%
|
13.58
-64.16%
|
37.88
+7.44%
|
35.26
|
| Current Deferred Revenue |
|
22.93
+68.86%
|
13.58
-64.16%
|
37.88
+7.44%
|
35.26
|
| Other Current Liabilities |
|
0.24
+8.52%
|
0.22
-57.44%
|
0.52
+72.94%
|
0.30
|
| Total Non Current Liabilities Net Minority Interest |
|
79.94
+7.08%
|
74.65
-21.50%
|
95.10
+128.38%
|
41.64
|
| Long Term Debt And Capital Lease Obligation |
|
68.50
-8.24%
|
74.65
-4.70%
|
78.33
+484.89%
|
13.39
|
| Long Term Capital Lease Obligation |
|
68.50
-8.24%
|
74.65
-4.70%
|
78.33
+484.89%
|
13.39
|
| Non Current Deferred Liabilities |
|
11.44
|
0.00
-100.00%
|
16.77
-40.11%
|
28.00
|
| Non Current Deferred Revenue |
|
11.44
|
0.00
-100.00%
|
16.77
-40.11%
|
28.00
|
| Other Non Current Liabilities |
|
—
|
—
|
—
|
0.25
|
| Stockholders Equity |
|
1,579.66
+89.04%
|
835.62
+111.56%
|
394.97
-19.42%
|
490.15
|
| Common Stock Equity |
|
1,579.66
+89.04%
|
835.62
+111.56%
|
394.97
-19.42%
|
490.15
|
| Capital Stock |
|
0.01
+14.29%
|
0.01
+16.67%
|
0.01
+0.00%
|
0.01
|
| Common Stock |
|
0.01
+14.29%
|
0.01
+16.67%
|
0.01
+0.00%
|
0.01
|
| Preferred Stock |
|
0.00
|
0.00
|
—
|
—
|
| Share Issued |
|
81.32
+25.32%
|
64.89
+16.74%
|
55.59
+0.99%
|
55.04
|
| Ordinary Shares Number |
|
81.32
+25.32%
|
64.89
+16.74%
|
55.59
+0.99%
|
55.04
|
| Additional Paid In Capital |
|
2,643.82
+66.10%
|
1,591.71
+71.84%
|
926.27
+5.39%
|
878.88
|
| Retained Earnings |
|
-1,065.96
-41.26%
|
-754.61
-42.18%
|
-530.75
-38.29%
|
-383.79
|
| Gains Losses Not Affecting Retained Earnings |
|
1.80
+221.21%
|
-1.49
-169.02%
|
-0.55
+88.85%
|
-4.95
|
| Other Equity Adjustments |
|
1.80
+221.21%
|
-1.49
-169.02%
|
-0.55
+88.85%
|
-4.95
|
| Total Equity Gross Minority Interest |
|
1,579.66
+89.04%
|
835.62
+111.56%
|
394.97
-19.42%
|
490.15
|
| Total Capitalization |
|
1,579.66
+89.04%
|
835.62
+111.56%
|
394.97
-19.42%
|
490.15
|
| Working Capital |
|
788.00
+78.08%
|
442.50
+38.44%
|
319.63
-8.17%
|
348.07
|
| Invested Capital |
|
1,579.66
+89.04%
|
835.62
+111.56%
|
394.97
-19.42%
|
490.15
|
| Total Debt |
|
82.25
-6.28%
|
87.76
+3.65%
|
84.67
+388.46%
|
17.34
|
| Capital Lease Obligations |
|
82.25
-6.28%
|
87.76
+3.65%
|
84.67
+388.46%
|
17.34
|
| Net Tangible Assets |
|
1,579.66
+89.04%
|
835.62
+111.56%
|
394.97
-19.42%
|
490.15
|
| Tangible Book Value |
|
1,579.66
+89.04%
|
835.62
+111.56%
|
394.97
-19.42%
|
490.15
|
| Available For Sale Securities |
|
771.16
+112.93%
|
362.16
+489.51%
|
61.43
-59.67%
|
152.33
|
| Investmentin Financial Assets |
|
771.16
+112.93%
|
362.16
+489.51%
|
61.43
-59.67%
|
152.33
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-232.89
-19.74%
|
-194.50
-89.16%
|
-102.83
+32.83%
|
-153.09
|
| Cash Flow From Continuing Operating Activities |
|
-232.89
-19.74%
|
-194.50
-89.16%
|
-102.83
+32.83%
|
-153.09
|
| Net Income From Continuing Operations |
|
-311.35
-39.08%
|
-223.86
-52.32%
|
-146.96
+5.07%
|
-154.81
|
| Depreciation Amortization Depletion |
|
8.31
+12.75%
|
7.37
+106.82%
|
3.56
+19.75%
|
2.98
|
| Depreciation And Amortization |
|
8.31
+12.75%
|
7.37
+106.82%
|
3.56
+19.75%
|
2.98
|
| Stock Based Compensation |
|
59.90
+8.89%
|
55.01
+27.58%
|
43.12
+21.53%
|
35.48
|
| Asset Impairment Charge |
|
3.86
-21.71%
|
4.92
|
0.00
|
0.00
|
| Operating Gains Losses |
|
—
|
—
|
-5.23
-688.19%
|
0.89
|
| Gain Loss On Investment Securities |
|
—
|
—
|
-5.23
-688.19%
|
0.89
|
| Gain Loss On Sale Of PPE |
|
—
|
—
|
0.00
|
0.00
|
| Change In Working Capital |
|
15.27
+163.69%
|
-23.97
-993.74%
|
2.68
+107.13%
|
-37.62
|
| Change In Receivables |
|
0.95
-94.68%
|
17.82
+209.79%
|
-16.23
-575.80%
|
-2.40
|
| Changes In Account Receivables |
|
0.00
-100.00%
|
15.00
+200.00%
|
-15.00
|
0.00
|
| Change In Prepaid Assets |
|
-2.36
+73.48%
|
-8.90
-354.00%
|
-1.96
-97.68%
|
-0.99
|
| Change In Payables And Accrued Expense |
|
5.41
+39.76%
|
3.87
-25.78%
|
5.22
+9.35%
|
4.77
|
| Change In Accrued Expense |
|
7.39
+76.72%
|
4.18
+31.45%
|
3.18
-29.63%
|
4.52
|
| Change In Payable |
|
-1.97
-543.00%
|
-0.31
-115.06%
|
2.04
+705.53%
|
0.25
|
| Change In Account Payable |
|
-1.97
-543.00%
|
-0.31
-115.06%
|
2.04
+705.53%
|
0.25
|
| Change In Other Working Capital |
|
13.64
+133.10%
|
-41.22
-433.35%
|
-7.73
+79.94%
|
-38.52
|
| Change In Other Current Assets |
|
2.67
+4.92%
|
2.54
-47.03%
|
4.80
+827.85%
|
0.52
|
| Change In Other Current Liabilities |
|
-5.04
-362.47%
|
1.92
-89.66%
|
18.58
+1950.80%
|
-1.00
|
| Investing Cash Flow |
|
-521.06
-28.95%
|
-404.08
-388.86%
|
139.89
+581.74%
|
20.52
|
| Cash Flow From Continuing Investing Activities |
|
-521.06
-28.95%
|
-404.08
-388.86%
|
139.89
+581.74%
|
20.52
|
| Net PPE Purchase And Sale |
|
-1.45
+88.71%
|
-12.84
+62.77%
|
-34.48
-1115.80%
|
-2.84
|
| Purchase Of PPE |
|
-1.45
+88.71%
|
-12.84
+62.77%
|
-34.48
-1115.80%
|
-2.84
|
| Capital Expenditure |
|
-1.45
+88.71%
|
-12.84
+62.77%
|
-34.48
-1115.80%
|
-2.84
|
| Net Investment Purchase And Sale |
|
-519.61
-32.81%
|
-391.24
-324.38%
|
174.37
+646.59%
|
23.36
|
| Purchase Of Investment |
|
-1,007.63
-11.81%
|
-901.23
-376.46%
|
-189.15
+57.59%
|
-445.97
|
| Sale Of Investment |
|
488.02
-4.31%
|
509.99
+40.29%
|
363.52
-22.55%
|
469.33
|
| Financing Cash Flow |
|
990.71
+62.72%
|
608.85
+14424.12%
|
4.19
-97.26%
|
153.00
|
| Cash Flow From Continuing Financing Activities |
|
990.71
+62.72%
|
608.85
+14424.12%
|
4.19
-97.26%
|
153.00
|
| Net Issuance Payments Of Debt |
|
-1.49
+5.20%
|
-1.58
-1973.68%
|
-0.08
+93.27%
|
-1.13
|
| Repayment Of Debt |
|
-1.49
+5.20%
|
-1.58
-1973.68%
|
-0.08
+93.27%
|
-1.13
|
| Long Term Debt Payments |
|
-1.49
+5.20%
|
-1.58
-1973.68%
|
-0.08
+93.27%
|
-1.13
|
| Net Long Term Debt Issuance |
|
-1.49
+5.20%
|
-1.58
-1973.68%
|
-0.08
+93.27%
|
-1.13
|
| Net Common Stock Issuance |
|
928.90
+55.69%
|
596.62
|
0.00
-100.00%
|
149.82
|
| Proceeds From Stock Option Exercised |
|
63.31
+358.47%
|
13.81
+223.52%
|
4.27
-0.84%
|
4.30
|
| Net Other Financing Charges |
|
—
|
—
|
—
|
—
|
| Changes In Cash |
|
236.76
+2204.69%
|
10.27
-75.10%
|
41.25
+101.89%
|
20.43
|
| Beginning Cash Position |
|
126.05
+8.87%
|
115.78
+55.35%
|
74.53
+37.77%
|
54.09
|
| End Cash Position |
|
362.81
+187.83%
|
126.05
+8.87%
|
115.78
+55.35%
|
74.53
|
| Free Cash Flow |
|
-234.34
-13.02%
|
-207.34
-51.01%
|
-137.31
+11.94%
|
-155.92
|
| Interest Paid Supplemental Data |
|
0.31
+51.46%
|
0.21
+27.16%
|
0.16
-9.50%
|
0.18
|
| Amortization Of Securities |
|
-8.88
+36.50%
|
-13.98
-167.41%
|
-5.23
-688.19%
|
0.89
|
| Common Stock Issuance |
|
928.90
+55.69%
|
596.62
|
0.00
-100.00%
|
149.82
|
| Issuance Of Capital Stock |
|
928.90
+55.69%
|
596.62
|
0.00
-100.00%
|
149.82
|
| Net Preferred Stock Issuance |
|
—
|
—
|
—
|
0.00
|
| Preferred Stock Issuance |
|
—
|
—
|
—
|
0.00
|
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
- 42026-04-16 View
- 42026-04-16 View
- 42026-04-16 View
- 42026-04-10 View
- 42026-04-01 View
- 42026-04-01 View
- 8-K2026-03-27 View
- 42026-03-25 View
- 42026-03-20 View
- 42026-03-11 View
- 42026-03-04 View
- 42026-03-04 View
- 42026-03-04 View
- 42026-03-04 View
- 42026-03-04 View
- 42026-03-04 View
- 42026-03-04 View
- 8-K2026-02-26 View
- 10-K2026-02-26 View
- 8-K2026-02-26 View
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|